Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 3.

van Herpen, Carla M L; Agarwala, Sanjiv S; Hauschild, Axel; Berking, Carola; Beck, J Thaddeus; Schadendorf, Dirk; Jansen, Rob; Queirolo, Paola; Ascierto, Paolo A; Blank, Christian U; Heinrich, Michael C; Pal, Rupam R; Derti, Adnan; Antona, Victor; Nauwelaerts, Heidi; Zubel, Angela; Dummer, Reinhard (2019). Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma. OncoTarget, 10(19):1850-1859.

Dummer, Reinhard; Schadendorf, Dirk; Ascierto, Paolo A; Arance, Ana; Dutriaux, Caroline; Di Giacomo, Anna Maria; Rutkowski, Piotr; Del Vecchio, Michele; Gutzmer, Ralf; Mandala, Mario; Thomas, Luc; Demidov, Lev; Garbe, Claus; Hogg, David; Liszkay, Gabriella; Queirolo, Paola; Wasserman, Ernesto; Ford, James; Weill, Marine; Sirulnik, L Andres; Jehl, Valentine; Bozón, Viviana; Long, Georgina V; Flaherty, Keith (2017). Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 18(4):435-445.

Ascierto, Paolo A; Schadendorf, Dirk; Berking, Carola; Agarwala, Sanjiv S; van Herpen, Carla Ml; Queirolo, Paola; Blank, Christian U; Hauschild, Axel; Beck, J Thaddeus; St-Pierre, Annie; Niazi, Faiz; Wandel, Simon; Peters, Malte; Zubel, Angela; Dummer, Reinhard (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncology, 14(3):249-256.

This list was generated on Sun Sep 22 14:35:09 2019 CEST.